[PDF][PDF] Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous …
M Crump, J Kuruvilla, S Couban… - Journal of Clinical …, 2014 - core.ac.uk
M Crump, J Kuruvilla, S Couban, DA MacDonald, V Kukreti, CT Kouroukis, M Rubinger…
Journal of Clinical Oncology, 2014•core.ac.ukRandomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus
Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Page 1 Randomized Comparison of
Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin
Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory
Aggressive Lymphomas: NCIC-CTG LY.12 Michael Crump, John Kuruvilla, Stephen Couban,
David A. MacDonald, Vishal Kukreti, C. Tom Kouroukis, Morel Rubinger,† Rena Buckstein, Kevin …
Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Page 1 Randomized Comparison of
Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin
Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory
Aggressive Lymphomas: NCIC-CTG LY.12 Michael Crump, John Kuruvilla, Stephen Couban,
David A. MacDonald, Vishal Kukreti, C. Tom Kouroukis, Morel Rubinger,† Rena Buckstein, Kevin …
Purpose
For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabinebased therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment.
core.ac.uk